Outlook Therapeutics (OTLK) Other financing activities (2016 - 2023)

Outlook Therapeutics (OTLK) has 6 years of Other financing activities data on file, last reported at $254964.0 in Q1 2023.

• Other financing activities for Q1 2023 came in at $254964.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2023 was $823894.0 (up 37.32% YoY), and the FY2023 annual result was $823894.0, up 37.32% from the prior year.
• Other financing activities eased to $254964.0 in Q1 2023 per OTLK's latest filing, from $568930.0 in the prior quarter.
• Over five years, Other financing activities peaked at $600000.0 in Q4 2021 and troughed at $8032.0 in Q4 2020.
• A 4-year average of $357981.5 and a median of $411947.0 in 2022 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2021 and 2022: Other financing activities surged 7370.12% in 2021, then fell 5.18% in 2022.
• A 4-year view of Other financing activities shows it stood at $8032.0 in 2020, then surged by 7370.12% to $600000.0 in 2021, then slipped by 5.18% to $568930.0 in 2022, then slumped by 55.19% to $254964.0 in 2023.
• Business Quant data shows OTLK's Other financing activities at $254964.0 in Q1 2023, $568930.0 in Q4 2022, and $600000.0 in Q4 2021.